Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,138.20 +59.34 (+0.73%) Bitcoin USD
63,885.75 +636.86 (+1.01%) CMC Crypto 200
1,335.33 -61.21 (-4.37%)
ProPhase Labs, Inc. (PRPH)
| Previous close | 4.9500 |
| Open | 4.9500 |
| Bid | 4.5800 x 100 |
| Ask | 5.0900 x 100 |
| Day's range | 4.6009 - 4.9500 |
| 52-week range | 4.0500 - 9.9400 |
| Volume | |
| Avg. volume | 51,467 |
| Market cap | 88.421M |
| Beta (5Y monthly) | -0.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 24 May 2022 |
| 1y target est | N/A |
- GlobeNewswire
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2024Date: Wednesday, May 1
- GlobeNewswire
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase’s business model, services, industry, financial results, valuation, and risks. The update note is available here. Highlights from the note include: ProPhase Labs Advances Cancer Treatment with Project ZenQ-AI - ProPhase Labs h
- GlobeNewswire
ProPhase Labs Unveils Project ZenQ-AI
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was
